Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer

Aravive, Inc. - Platinum Resistant Ovarian CancerПодробнее

Unmet clinical needs for platinum-resistant ovarian cancer patientsПодробнее

Managing Platinum-Resistant Ovarian CancerПодробнее

Tackling Platinum Resistant Ovarian CancerПодробнее

Dr. Arend on the Rationale of Novel Combinations in Gynecologic CancerПодробнее

Updates on Promising Progress in Platinum Resistant Ovarian CancerПодробнее

Dr. Arend on Niraparib With Bevacizumab in Ovarian CancerПодробнее

The Future of Care in Advanced Ovarian CancerПодробнее

Unmet Needs in Ovarian CancerПодробнее

Dr. Arend on Novel Combination Strategies in Gynecologic CancerПодробнее

ASCO: New Hope For Platinum-Resistant Ovarian CancerПодробнее

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian CancerПодробнее

Emerging opportunities in platinum-resistant recurrent ovarian cancerПодробнее

Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian CancerПодробнее

Phase I dose expansion results of CYT-0851 plus capecitabine in platinum-resistant ovarian cancerПодробнее

Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancerПодробнее

Diagnosis of Metastatic Platinum-Resistant Ovarian CancerПодробнее

Dr. Arend Discusses Targets in Endometrial CancerПодробнее

Dr. Sehouli Discusses Unmet Needs in Ovarian CancerПодробнее